L
Leticia Kawano-Dourado
Researcher at University of São Paulo
Publications - 58
Citations - 3009
Leticia Kawano-Dourado is an academic researcher from University of São Paulo. The author has contributed to research in topics: Medicine & Interstitial lung disease. The author has an hindex of 11, co-authored 47 publications receiving 1647 citations. Previous affiliations of Leticia Kawano-Dourado include University of Paris.
Papers
More filters
Journal ArticleDOI
Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial.
Bruno Martins Tomazini,Israel Silva Maia,Alexandre Biasi Cavalcanti,Otavio Berwanger,Regis Goulart Rosa,Viviane C Veiga,Alvaro Avezum,Renato D. Lopes,Flavia Regina Bueno,Maria Vitoria Aparecida Oliveira Silva,Franca Pellison Baldassare,Eduardo L. V. Costa,Ricardo Antonio Bonifácio Moura,Michele Ouriques Honorato,André Nathan Costa,Lucas P. Damiani,Thiago Lisboa,Leticia Kawano-Dourado,Fernando G. Zampieri,Guilherme B Olivato,Cassia Righy,Cristina Prata Amendola,Roberta Muriel Longo Roepke,Daniela H M Freitas,Daniel Neves Forte,Flávio Geraldo Resende Freitas,Caio C. Fernandes,Livia Maria Garcia Melro,Gedealvares F S Junior,Douglas Costa Morais,Stevin Zung,Flávia Ribeiro Machado,Luciano Cesar Pontes Azevedo,Coalition Covid Brazil Iii Investigators +33 more
TL;DR: Among patients with COVID-19 and moderate or severe ARDS, use of intravenous dexamethasone plus standard care compared with standard care alone resulted in a statistically significant increase in the number of ventilator-free days over 28 days.
Journal ArticleDOI
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19.
Alexandre Biasi Cavalcanti,Fernando G. Zampieri,Regis Goulart Rosa,Luciano Cesar Pontes Azevedo,Viviane C Veiga,Alvaro Avezum,Lucas P. Damiani,Aline Marcadenti,Leticia Kawano-Dourado,Thiago Lisboa,Debora L. M. Junqueira,Pedro Gabriel Melo de Barros e Silva,Lucas Tramujas,Erlon Oliveira de Abreu-Silva,Lígia Nasi Laranjeira,Aline T. Soares,Leandro S. Echenique,Adriano José Pereira,Flávio Geraldo Resende Freitas,Otavio Gebara,Vicente C.S. Dantas,Remo H.M. Furtado,Eveline P. Milan,Nicole A. Golin,Fábio F. Cardoso,Israel Silva Maia,Conrado R. Hoffmann Filho,Adrian P.M. Kormann,Roberto Bleuel Amazonas,Monalisa Fernanda Bocchi de Oliveira,Ary Serpa-Neto,Maicon Falavigna,Renato D. Lopes,Flávia Ribeiro Machado,Otavio Berwanger +34 more
TL;DR: Among patients hospitalized with mild-to-moderate Covid-19, the use of hydroxychloroquine, alone or with azithromycin, did not improve clinical status at 15 days as compared with standard care.
Journal ArticleDOI
A living WHO guideline on drugs for covid-19
Bram Rochwerg,Arnav Agarwal,Reed A C Siemieniuk,Thomas Agoritsas,Francois Lamontagne,Lisa Askie,Lyubov Lytvyn,Yee Sin Leo,Helen Macdonald,Linan Zeng,Wagdy Amin,Erlina Burhan,Frédérique Jacquerioz Bausch,Carolyn S. Calfee,Maurizio Cecconi,Duncan Chanda,Bin Du,Heike Geduld,Patrick Gee,Nerina Harley,Madiha Hashimi,Beverly Hunt,Sushil K. Kabra,Seema Kanda,Leticia Kawano-Dourado,Yae-Jean Kim,Niranjan Kissoon,Arthur Kwizera,Imelda Mahaka,Hela Manai,Greta Mino,Emmanuel Nsutebu,Jacobus Preller,Natalia Pshenichnaya,Nida Qadir,Saniya Sabzwari,Rohit Sarin,Manu Shankar-Hari,Mike Sharland,Yinzhong Shen,Shalini Sri Ranganathan,João Paulo Souza,Miriam Stegemann,An De Sutter,Sebastian Ugarte,Sridhar Venkatapuram,Vu Quoc Dat,Dubula Vuyiseka,Ananda Wijewickrama,Brittany J. Maguire,Dena Zeraatkar,Jessica J Bartoszko,Long Ge,Long Ge,Romina Brignardello-Petersen,Andrew Owen,Gordon H. Guyatt,Janet V. Diaz,Michael Jacobs,Per Olav Vandvik +59 more
TL;DR: A standing international panel of content experts, patients, clinicians, and methodologists, free from relevant conflicts of interest, produce recommendations for clinical practice, containing a strong recommendation for systemic corticosteroids in patients with severe and critical covid-19, and a weak or conditional recommendation against systemic cortiosteroids for non-severe patients.
Journal ArticleDOI
Remdesivir for severe covid-19: a clinical practice guideline.
Bram Rochwerg,Arnav Agarwal,Arnav Agarwal,Linan Zeng,Linan Zeng,Yee Sin Leo,John Adabie Appiah,Thomas Agoritsas,Jessica J Bartoszko,Romina Brignardello-Petersen,Begüm Ergan,Long Ge,Heike Geduld,Hayley B. Gershengorn,Hayley B. Gershengorn,Hela Manai,Minhua Huang,Francois Lamontagne,Seema Kanda,Leticia Kawano-Dourado,Linda Kurian,Arthur Kwizera,Srinivas Murthy,Nida Qadir,Reed A C Siemieniuk,Maria Asuncion A. Silvestre,Per Olav Vandvik,Zhikang Ye,Dena Zeraatkar,Gordon Guyatt,Gordon Guyatt +30 more
TL;DR: This guideline was triggered by the ACTT-1 trial and issued a weak recommendation for the use of remdesivir in severe covid-19 while recommending continuation of active enrolment of patients into ongoing randomised controlled trials examining remdesvir.
Journal ArticleDOI
Methotrexate and rheumatoid arthritis associated interstitial lung disease.
Pierre-Antoine Juge,Joyce S. Lee,Jessica Lau,Leticia Kawano-Dourado,Jorge Rojas Serrano,Marco Sebastiani,Gouri Koduri,Eric L. Matteson,Karina Bonfiglioli,Marcio Valente Yamada Sawamura,Ronaldo Adib Kairalla,Lorenzo Cavagna,Emanuele Bozzalla Cassione,Andreina Teresa Manfredi,Mayra Mejía,Pedro Rodríguez-Henriquez,Montserrat I González-Pérez,Ramcés Falfán-Valencia,Ivette Buendía-Roldán,Gloria Pérez-Rubio,Esther Ebstein,Steven Gazal,Steven Gazal,Raphael Borie,Sébastien Ottaviani,Caroline Kannengiesser,Benoit Wallaert,Yurdagul Uzunhan,Hilario Nunes,Dominique Valeyre,Nathalie Saidenberg-Kermanac’h,Marie-Christophe Boissier,Lidwine Wemeau-Stervinou,René-Marc Flipo,Sylvain Marchand-Adam,Pascal Richette,Pascal Richette,Yannick Allanore,Yannick Allanore,Claire Dromer,Marie-Elise Truchetet,Christophe Richez,Thierry Schaeverbeke,Huguette Lioté,Gabriel Thabut,Kevin D. Deane,Joshua J. Solomon,Tracy J. Doyle,Jay H. Ryu,Ivan O. Rosas,V. Michael Holers,Catherine Boileau,Marie-Pierre Debray,Raphaël Porcher,David A. Schwartz,Robert Vassallo,Bruno Crestani,Philippe Dieudé +57 more
TL;DR: The results suggest that MTX use is not associated with an increased risk of RA-ILD in patients with RA, and that ILD was detected later in MTX-treated patients.